Skip to content

Author

X. Pundole

We have 2 of 15 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy

Abstract Background Platinum-etoposide (PE) chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor is the current first-line (1L) standard of care for extensive-stage small cell lung cancer (ES-SCLC). Real-world evidence describing outcomes across induction and maintenance phases remains limited....

Yi-Shao Liu, P. Desai, H. Khurshid et al. · 0 citations
Open access Oct 2026

Real-world treatment patterns, outcomes, and burden of early progression in small cell lung cancer (SCLC) in the US.

704 Background: Treatment options for patients with SCLC are limited, and prognosis remains poor. Most patients develop resistance to or relapse after first-line (1L) therapies within the first year in both limited-stage (LS) and extensive-stage (ES). The economic burden of SCLC is not well characterized. This...

Su Zhang, Franziska Dirnberger, Sunny Ubi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.